Share Price and Basic Stock Data
Last Updated: February 6, 2026, 3:15 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Omkar Speciality Chemicals Ltd operates in the specialty chemicals sector, focusing on producing a diverse array of chemical products. The company’s revenue exhibited significant fluctuations over the past years, with sales reporting a high of ₹210 Cr in March 2014, followed by a notable decline to ₹23 Cr in March 2022 and further down to ₹19 Cr in the trailing twelve months (TTM). Quarterly sales data reveals that the company faced challenges, particularly in June 2022, where sales stood at ₹3.74 Cr, a stark contrast to the ₹18.97 Cr reported in September 2019. Such volatility raises questions about the company’s market positioning and operational efficiency. The company’s ability to stabilize and grow revenue remains critical as it navigates a competitive landscape, characterized by increasing demand for specialty chemicals in various industries, including pharmaceuticals and agriculture.
Profitability and Efficiency Metrics
Omkar Speciality Chemicals has faced challenges in maintaining profitability, as reflected in its operating profit margin (OPM), which stood at a negative 25.40% in June 2022. The company reported a net profit of ₹-13 Cr for the TTM, indicating persistent losses over recent years. The operating profit fluctuated significantly, with the highest being ₹21 Cr in March 2011, but declining to a loss of ₹6 Cr in March 2022. The interest coverage ratio (ICR) of 4.04x suggests that the company can comfortably cover its interest obligations, although the overall profitability remains a concern. Efficiency metrics such as Days Sales Outstanding (DSO) have seen a drastic shift; the cash conversion cycle (CCC) stood at -143 days, indicating potential issues in inventory management and receivables, which can adversely affect cash flow and operational stability.
Balance Sheet Strength and Financial Ratios
Omkar Speciality Chemicals’ balance sheet reveals a concerning picture, with total borrowings amounting to ₹226 Cr against reserves of ₹-192 Cr, indicating a negative equity position. This raises red flags regarding the company’s solvency and long-term sustainability. The price-to-book value ratio (P/BV) is reported at 1.84x, which is relatively high compared to typical industry standards, suggesting that investors may be paying a premium for the company’s shares despite its challenging financial condition. The company’s return on capital employed (ROCE) stood at 10.5%, which may be considered low compared to sector norms, reflecting suboptimal asset utilization. Furthermore, the working capital management is alarming, with a working capital cycle of -3,296 days, indicating significant inefficiencies that could hinder operational capabilities and future growth.
Shareholding Pattern and Investor Confidence
The shareholding structure of Omkar Speciality Chemicals indicates a low level of institutional investment, with foreign institutional investors (FIIs) holding just 0.06% and domestic institutional investors (DIIs) at a mere 0.01%. Promoters hold 14.71% of the shares, a significant decline from 27.62% in September 2019, which may signal waning confidence among the founding members. The public holds a substantial 85.22%, reflecting a broad base of retail investors but potentially indicating a lack of institutional backing, which is often seen as a sign of confidence in a company’s prospects. The number of shareholders has remained relatively stable at 19,430, suggesting that retail interest persists despite the company’s financial challenges. This pattern could affect the stock’s liquidity and may hinder its ability to attract further investment unless operational performance improves.
Outlook, Risks, and Final Insight
The outlook for Omkar Speciality Chemicals is contingent on its ability to stabilize operations and return to profitability. The company’s significant debt levels pose a risk, particularly in a rising interest rate environment, which could further strain cash flows. Additionally, the negative equity position and ongoing operational losses raise concerns about its long-term viability. However, the specialty chemicals sector presents growth opportunities, driven by increasing demand across various industries. If the company can effectively manage its operational inefficiencies and leverage its existing capabilities, it may navigate towards recovery. Conversely, failure to address these critical issues could lead to further deterioration in financial health, impacting shareholder value. A strategic focus on cost management, operational efficiency, and potential diversification may serve as pathways to regain investor confidence and enhance market positioning.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 370 Cr. | 40.3 | 68.7/35.0 | 23.0 | 20.5 | 1.00 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.9 Cr. | 65.0 | 88.8/52.0 | 15.3 | 89.6 | 1.53 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 51.0 Cr. | 750 | 899/600 | 17.2 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,230 Cr. | 71.2 | 111/68.2 | 21.4 | 22.0 | 0.69 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 559 Cr. | 224 | 377/208 | 20.0 | 93.8 | 1.11 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 13,023.12 Cr | 744.51 | 58.23 | 182.97 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.70 | 18.97 | 14.43 | 12.79 | 5.14 | 16.86 | 12.16 | 10.97 | 7.36 | 4.23 | 6.34 | 5.05 | 3.74 |
| Expenses | 10.31 | 17.88 | 14.10 | 14.83 | 4.86 | 13.80 | 9.20 | 10.78 | 7.76 | 6.55 | 6.21 | 8.16 | 4.69 |
| Operating Profit | 0.39 | 1.09 | 0.33 | -2.04 | 0.28 | 3.06 | 2.96 | 0.19 | -0.40 | -2.32 | 0.13 | -3.11 | -0.95 |
| OPM % | 3.64% | 5.75% | 2.29% | -15.95% | 5.45% | 18.15% | 24.34% | 1.73% | -5.43% | -54.85% | 2.05% | -61.58% | -25.40% |
| Other Income | 0.31 | 0.04 | 0.01 | 0.08 | 1.01 | 0.07 | 0.55 | 4.16 | 0.02 | 0.72 | 0.01 | 0.21 | 0.12 |
| Interest | 1.15 | 1.24 | 1.47 | 1.08 | 1.25 | 1.59 | 1.52 | 1.21 | 1.43 | 1.49 | 1.57 | 1.58 | 1.69 |
| Depreciation | 1.69 | 1.66 | 1.98 | 1.25 | 1.03 | 0.98 | 0.98 | 0.57 | 0.47 | 0.47 | 0.40 | 0.44 | 0.39 |
| Profit before tax | -2.14 | -1.77 | -3.11 | -4.29 | -0.99 | 0.56 | 1.01 | 2.57 | -2.28 | -3.56 | -1.83 | -4.92 | -2.91 |
| Tax % | 1.40% | 67.23% | 31.51% | 26.11% | 34.34% | 71.43% | 39.60% | -0.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -2.17 | -2.96 | -4.09 | -5.42 | -1.34 | 0.16 | 0.61 | 2.58 | -2.28 | -3.56 | -1.84 | -4.92 | -2.90 |
| EPS in Rs | -1.05 | -1.44 | -1.99 | -2.63 | -0.65 | 0.08 | 0.30 | 1.25 | -1.11 | -1.73 | -0.89 | -2.39 | -1.41 |
Last Updated: January 11, 2026, 5:17 am
Below is a detailed analysis of the quarterly data for Omkar Speciality Chemicals Ltd based on the most recent figures (Jun 2022) and their trends compared to the previous period:
- For Sales, as of Jun 2022, the value is 3.74 Cr.. The value appears to be declining and may need further review. It has decreased from 5.05 Cr. (Mar 2022) to 3.74 Cr., marking a decrease of 1.31 Cr..
- For Expenses, as of Jun 2022, the value is 4.69 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 8.16 Cr. (Mar 2022) to 4.69 Cr., marking a decrease of 3.47 Cr..
- For Operating Profit, as of Jun 2022, the value is -0.95 Cr.. The value appears strong and on an upward trend. It has increased from -3.11 Cr. (Mar 2022) to -0.95 Cr., marking an increase of 2.16 Cr..
- For OPM %, as of Jun 2022, the value is -25.40%. The value appears strong and on an upward trend. It has increased from -61.58% (Mar 2022) to -25.40%, marking an increase of 36.18%.
- For Other Income, as of Jun 2022, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.21 Cr. (Mar 2022) to 0.12 Cr., marking a decrease of 0.09 Cr..
- For Interest, as of Jun 2022, the value is 1.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.58 Cr. (Mar 2022) to 1.69 Cr., marking an increase of 0.11 Cr..
- For Depreciation, as of Jun 2022, the value is 0.39 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.44 Cr. (Mar 2022) to 0.39 Cr., marking a decrease of 0.05 Cr..
- For Profit before tax, as of Jun 2022, the value is -2.91 Cr.. The value appears strong and on an upward trend. It has increased from -4.92 Cr. (Mar 2022) to -2.91 Cr., marking an increase of 2.01 Cr..
- For Tax %, as of Jun 2022, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2022) which recorded 0.00%.
- For Net Profit, as of Jun 2022, the value is -2.90 Cr.. The value appears strong and on an upward trend. It has increased from -4.92 Cr. (Mar 2022) to -2.90 Cr., marking an increase of 2.02 Cr..
- For EPS in Rs, as of Jun 2022, the value is -1.41. The value appears strong and on an upward trend. It has increased from -2.39 (Mar 2022) to -1.41, marking an increase of 0.98.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:52 am
| Metric | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 107 | 167 | 202 | 210 | 193 | 319 | 317 | 198 | 43 | 57 | 45 | 23 | 19 |
| Expenses | 85 | 134 | 165 | 177 | 164 | 274 | 259 | 241 | 44 | 57 | 38 | 29 | 26 |
| Operating Profit | 21 | 33 | 36 | 33 | 29 | 45 | 57 | -43 | -1 | -0 | 7 | -6 | -6 |
| OPM % | 20% | 20% | 18% | 16% | 15% | 14% | 18% | -22% | -3% | -0% | 16% | -25% | -32% |
| Other Income | 1 | 4 | 6 | 6 | 5 | 9 | -161 | -49 | 12 | 0 | 5 | 1 | 1 |
| Interest | 5 | 8 | 7 | 12 | 11 | 17 | 22 | 26 | 15 | 5 | 6 | 6 | 6 |
| Depreciation | 2 | 6 | 6 | 6 | 2 | 4 | 11 | 8 | 8 | 7 | 4 | 2 | 2 |
| Profit before tax | 15 | 23 | 29 | 21 | 20 | 33 | -137 | -127 | -12 | -11 | 3 | -13 | -13 |
| Tax % | 31% | 29% | 28% | 30% | 12% | 33% | -20% | -18% | 46% | 29% | 36% | 0% | |
| Net Profit | 10 | 16 | 21 | 15 | 18 | 22 | -109 | -104 | -17 | -15 | 2 | -13 | -13 |
| EPS in Rs | 5.17 | 8.39 | 10.61 | 7.45 | 8.70 | 10.78 | -53.09 | -50.47 | -8.19 | -7.10 | 0.98 | -6.12 | -6.42 |
| Dividend Payout % | 19% | 15% | 14% | 20% | 17% | 14% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2011-2012 | 2012-2013 | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 60.00% | 31.25% | -28.57% | 20.00% | 22.22% | -595.45% | 4.59% | 83.65% | 11.76% | 113.33% | -750.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -28.75% | -59.82% | 48.57% | 2.22% | -617.68% | 600.04% | 79.07% | -71.89% | 101.57% | -863.33% |
Omkar Speciality Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2011-2012 to 2021-2022.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -18% |
| 5 Years: | -41% |
| 3 Years: | -19% |
| TTM: | -59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| TTM: | -345% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -3% |
| 3 Years: | -33% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: April 13, 2025, 3:05 pm
| Month | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 20 | 20 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 73 | 86 | 107 | 118 | 142 | 161 | -23 | -146 | -169 | -183 | -179 | -192 |
| Borrowings | 45 | 78 | 118 | 154 | 176 | 186 | 181 | 233 | 230 | 233 | 228 | 226 |
| Other Liabilities | 35 | 33 | 38 | 50 | 50 | 80 | 129 | 28 | 26 | 26 | 17 | 18 |
| Total Liabilities | 172 | 217 | 283 | 342 | 389 | 447 | 307 | 136 | 107 | 97 | 86 | 72 |
| Fixed Assets | 21 | 36 | 44 | 43 | 68 | 78 | 83 | 76 | 68 | 53 | 28 | 26 |
| CWIP | 18 | 31 | 40 | 69 | 107 | 113 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 2 | 11 | 14 | 14 | 14 | 0 | 11 | 0 | 0 | 1 | 0 |
| Other Assets | 133 | 148 | 187 | 217 | 199 | 242 | 224 | 49 | 38 | 44 | 58 | 46 |
| Total Assets | 172 | 217 | 283 | 342 | 389 | 447 | 307 | 136 | 107 | 97 | 86 | 72 |
Below is a detailed analysis of the balance sheet data for Omkar Speciality Chemicals Ltd based on the most recent figures (Mar 2022) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2022, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2021) which recorded 21.00 Cr..
- For Reserves, as of Mar 2022, the value is -192.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -179.00 Cr. (Mar 2021) to -192.00 Cr., marking a decline of 13.00 Cr..
- For Borrowings, as of Mar 2022, the value is 226.00 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 228.00 Cr. (Mar 2021) to 226.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Mar 2022, the value is 18.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2021) to 18.00 Cr., marking an increase of 1.00 Cr..
- For Total Liabilities, as of Mar 2022, the value is 72.00 Cr.. The value appears to be improving (decreasing). It has decreased from 86.00 Cr. (Mar 2021) to 72.00 Cr., marking a decrease of 14.00 Cr..
- For Fixed Assets, as of Mar 2022, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2021) to 26.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Mar 2022, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2021) which recorded 0.00 Cr..
- For Investments, as of Mar 2022, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2021) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Mar 2022, the value is 46.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2021) to 46.00 Cr., marking a decrease of 12.00 Cr..
- For Total Assets, as of Mar 2022, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 86.00 Cr. (Mar 2021) to 72.00 Cr., marking a decrease of 14.00 Cr..
However, the Borrowings (226.00 Cr.) are higher than the Reserves (-192.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -24.00 | -45.00 | -82.00 | -121.00 | -147.00 | -141.00 | -124.00 | -276.00 | -231.00 | -233.00 | -221.00 | -232.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 84 | 111 | 148 | 129 | 117 | 90 | 19 | 74 | 30 | 111 | 33 |
| Inventory Days | 147 | 168 | 170 | 156 | 149 | 99 | 110 | 8 | 37 | 31 | 18 | 40 |
| Days Payable | 106 | 81 | 73 | 94 | 96 | 81 | 184 | 32 | 259 | 148 | 139 | 215 |
| Cash Conversion Cycle | 135 | 172 | 209 | 210 | 181 | 135 | 16 | -5 | -147 | -86 | -10 | -143 |
| Working Capital Days | 68 | 5 | 26 | -10 | -89 | 38 | -81 | -296 | -1,361 | -1,002 | -1,065 | -3,296 |
| ROCE % | 22% | 19% | 17% | 12% | 10% | 14% | 18% | -34% | -8% | -8% | 7% | -11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 14.88 | 12.03 | 6.91 | 10.47 | 8.15 |
| Diluted EPS (Rs.) | 14.88 | 12.03 | 6.59 | 10.46 | 8.15 |
| Cash EPS (Rs.) | 19.26 | 16.82 | 13.05 | 13.88 | 11.03 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 94.99 | 81.92 | 69.91 | 64.74 | 53.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 94.99 | 81.92 | 69.91 | 64.74 | 53.71 |
| Revenue From Operations / Share (Rs.) | 200.90 | 128.84 | 122.42 | 107.85 | 85.06 |
| PBDIT / Share (Rs.) | 39.96 | 25.79 | 23.53 | 22.53 | 18.53 |
| PBIT / Share (Rs.) | 35.58 | 20.77 | 17.39 | 19.12 | 15.65 |
| PBT / Share (Rs.) | 25.45 | 13.73 | 10.04 | 15.29 | 11.52 |
| Net Profit / Share (Rs.) | 14.88 | 11.80 | 6.91 | 10.47 | 8.15 |
| NP After MI And SOA / Share (Rs.) | 14.88 | 11.80 | 6.91 | 10.47 | 8.15 |
| PBDIT Margin (%) | 19.89 | 20.01 | 19.22 | 20.88 | 21.78 |
| PBIT Margin (%) | 17.70 | 16.11 | 14.20 | 17.72 | 18.39 |
| PBT Margin (%) | 12.66 | 10.65 | 8.20 | 14.17 | 13.54 |
| Net Profit Margin (%) | 7.40 | 9.15 | 5.64 | 9.71 | 9.58 |
| NP After MI And SOA Margin (%) | 7.40 | 9.15 | 5.64 | 9.71 | 9.58 |
| Return on Networth / Equity (%) | 15.66 | 14.40 | 9.88 | 16.17 | 15.17 |
| Return on Capital Employeed (%) | 24.08 | 18.45 | 16.75 | 20.38 | 23.00 |
| Return On Assets (%) | 5.25 | 5.06 | 3.36 | 6.24 | 6.73 |
| Long Term Debt / Equity (X) | 0.48 | 0.35 | 0.47 | 0.42 | 0.24 |
| Total Debt / Equity (X) | 1.06 | 1.19 | 1.39 | 1.14 | 0.90 |
| Asset Turnover Ratio (%) | 0.64 | 0.48 | 0.62 | 0.77 | 0.85 |
| Current Ratio (X) | 0.97 | 0.83 | 1.08 | 1.32 | 1.33 |
| Quick Ratio (X) | 0.61 | 0.47 | 0.65 | 0.81 | 0.82 |
| Inventory Turnover Ratio (X) | 2.22 | 1.49 | 1.38 | 2.05 | 2.60 |
| Dividend Payout Ratio (NP) (%) | 10.08 | 12.71 | 21.71 | 14.32 | 15.33 |
| Dividend Payout Ratio (CP) (%) | 7.78 | 8.91 | 11.49 | 10.80 | 11.32 |
| Earning Retention Ratio (%) | 89.92 | 87.29 | 78.29 | 85.68 | 84.67 |
| Cash Earning Retention Ratio (%) | 92.22 | 91.09 | 88.51 | 89.20 | 88.68 |
| Interest Coverage Ratio (X) | 4.04 | 3.66 | 3.22 | 5.88 | 4.49 |
| Interest Coverage Ratio (Post Tax) (X) | 2.52 | 2.68 | 1.95 | 3.73 | 2.98 |
| Enterprise Value (Cr.) | 556.39 | 517.22 | 461.39 | 345.22 | 178.59 |
| EV / Net Operating Revenue (X) | 1.35 | 1.95 | 1.92 | 1.63 | 1.07 |
| EV / EBITDA (X) | 6.77 | 9.75 | 9.99 | 7.81 | 4.91 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 1.25 | 1.20 | 1.06 | 0.69 |
| Retention Ratios (%) | 89.91 | 87.28 | 78.28 | 85.67 | 84.66 |
| Price / BV (X) | 1.84 | 1.97 | 2.10 | 1.77 | 1.10 |
| Price / Net Operating Revenue (X) | 0.86 | 1.25 | 1.20 | 1.06 | 0.69 |
| EarningsYield | 0.08 | 0.07 | 0.04 | 0.09 | 0.13 |
After reviewing the key financial ratios for Omkar Speciality Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 15) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 16, the value is 14.88. This value is within the healthy range. It has increased from 12.03 (Mar 15) to 14.88, marking an increase of 2.85.
- For Diluted EPS (Rs.), as of Mar 16, the value is 14.88. This value is within the healthy range. It has increased from 12.03 (Mar 15) to 14.88, marking an increase of 2.85.
- For Cash EPS (Rs.), as of Mar 16, the value is 19.26. This value is within the healthy range. It has increased from 16.82 (Mar 15) to 19.26, marking an increase of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 94.99. It has increased from 81.92 (Mar 15) to 94.99, marking an increase of 13.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 94.99. It has increased from 81.92 (Mar 15) to 94.99, marking an increase of 13.07.
- For Revenue From Operations / Share (Rs.), as of Mar 16, the value is 200.90. It has increased from 128.84 (Mar 15) to 200.90, marking an increase of 72.06.
- For PBDIT / Share (Rs.), as of Mar 16, the value is 39.96. This value is within the healthy range. It has increased from 25.79 (Mar 15) to 39.96, marking an increase of 14.17.
- For PBIT / Share (Rs.), as of Mar 16, the value is 35.58. This value is within the healthy range. It has increased from 20.77 (Mar 15) to 35.58, marking an increase of 14.81.
- For PBT / Share (Rs.), as of Mar 16, the value is 25.45. This value is within the healthy range. It has increased from 13.73 (Mar 15) to 25.45, marking an increase of 11.72.
- For Net Profit / Share (Rs.), as of Mar 16, the value is 14.88. This value is within the healthy range. It has increased from 11.80 (Mar 15) to 14.88, marking an increase of 3.08.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is 14.88. This value is within the healthy range. It has increased from 11.80 (Mar 15) to 14.88, marking an increase of 3.08.
- For PBDIT Margin (%), as of Mar 16, the value is 19.89. This value is within the healthy range. It has decreased from 20.01 (Mar 15) to 19.89, marking a decrease of 0.12.
- For PBIT Margin (%), as of Mar 16, the value is 17.70. This value is within the healthy range. It has increased from 16.11 (Mar 15) to 17.70, marking an increase of 1.59.
- For PBT Margin (%), as of Mar 16, the value is 12.66. This value is within the healthy range. It has increased from 10.65 (Mar 15) to 12.66, marking an increase of 2.01.
- For Net Profit Margin (%), as of Mar 16, the value is 7.40. This value is within the healthy range. It has decreased from 9.15 (Mar 15) to 7.40, marking a decrease of 1.75.
- For NP After MI And SOA Margin (%), as of Mar 16, the value is 7.40. This value is below the healthy minimum of 8. It has decreased from 9.15 (Mar 15) to 7.40, marking a decrease of 1.75.
- For Return on Networth / Equity (%), as of Mar 16, the value is 15.66. This value is within the healthy range. It has increased from 14.40 (Mar 15) to 15.66, marking an increase of 1.26.
- For Return on Capital Employeed (%), as of Mar 16, the value is 24.08. This value is within the healthy range. It has increased from 18.45 (Mar 15) to 24.08, marking an increase of 5.63.
- For Return On Assets (%), as of Mar 16, the value is 5.25. This value is within the healthy range. It has increased from 5.06 (Mar 15) to 5.25, marking an increase of 0.19.
- For Long Term Debt / Equity (X), as of Mar 16, the value is 0.48. This value is within the healthy range. It has increased from 0.35 (Mar 15) to 0.48, marking an increase of 0.13.
- For Total Debt / Equity (X), as of Mar 16, the value is 1.06. This value exceeds the healthy maximum of 1. It has decreased from 1.19 (Mar 15) to 1.06, marking a decrease of 0.13.
- For Asset Turnover Ratio (%), as of Mar 16, the value is 0.64. It has increased from 0.48 (Mar 15) to 0.64, marking an increase of 0.16.
- For Current Ratio (X), as of Mar 16, the value is 0.97. This value is below the healthy minimum of 1.5. It has increased from 0.83 (Mar 15) to 0.97, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 16, the value is 0.61. This value is below the healthy minimum of 1. It has increased from 0.47 (Mar 15) to 0.61, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 16, the value is 2.22. This value is below the healthy minimum of 4. It has increased from 1.49 (Mar 15) to 2.22, marking an increase of 0.73.
- For Dividend Payout Ratio (NP) (%), as of Mar 16, the value is 10.08. This value is below the healthy minimum of 20. It has decreased from 12.71 (Mar 15) to 10.08, marking a decrease of 2.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 16, the value is 7.78. This value is below the healthy minimum of 20. It has decreased from 8.91 (Mar 15) to 7.78, marking a decrease of 1.13.
- For Earning Retention Ratio (%), as of Mar 16, the value is 89.92. This value exceeds the healthy maximum of 70. It has increased from 87.29 (Mar 15) to 89.92, marking an increase of 2.63.
- For Cash Earning Retention Ratio (%), as of Mar 16, the value is 92.22. This value exceeds the healthy maximum of 70. It has increased from 91.09 (Mar 15) to 92.22, marking an increase of 1.13.
- For Interest Coverage Ratio (X), as of Mar 16, the value is 4.04. This value is within the healthy range. It has increased from 3.66 (Mar 15) to 4.04, marking an increase of 0.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 16, the value is 2.52. This value is below the healthy minimum of 3. It has decreased from 2.68 (Mar 15) to 2.52, marking a decrease of 0.16.
- For Enterprise Value (Cr.), as of Mar 16, the value is 556.39. It has increased from 517.22 (Mar 15) to 556.39, marking an increase of 39.17.
- For EV / Net Operating Revenue (X), as of Mar 16, the value is 1.35. This value is within the healthy range. It has decreased from 1.95 (Mar 15) to 1.35, marking a decrease of 0.60.
- For EV / EBITDA (X), as of Mar 16, the value is 6.77. This value is within the healthy range. It has decreased from 9.75 (Mar 15) to 6.77, marking a decrease of 2.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 16, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 1.25 (Mar 15) to 0.86, marking a decrease of 0.39.
- For Retention Ratios (%), as of Mar 16, the value is 89.91. This value exceeds the healthy maximum of 70. It has increased from 87.28 (Mar 15) to 89.91, marking an increase of 2.63.
- For Price / BV (X), as of Mar 16, the value is 1.84. This value is within the healthy range. It has decreased from 1.97 (Mar 15) to 1.84, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 16, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 1.25 (Mar 15) to 0.86, marking a decrease of 0.39.
- For EarningsYield, as of Mar 16, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 15) to 0.08, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Omkar Speciality Chemicals Ltd:
- Net Profit Margin: 7.4%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 24.08% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.66% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.61
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 58.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.4%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Mahalasa Narayani, Thane Maharashtra 421503 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pravin S Herlekar | Chairman & Managing Director |
| Mr. Subhash Ambatkar | Executive Director |
| Mrs. Sanjivani S Patare | Independent Director |
| Ms. Archana Dakhale | Independent Director |
| Mr. Kannan Thevar | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Omkar Speciality Chemicals Ltd?
Omkar Speciality Chemicals Ltd's intrinsic value (as of 06 February 2026) is ₹186.83 which is 3689.66% higher the current market price of ₹4.93, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹10.1 Cr. market cap, FY2025-2026 high/low of ₹8.38/4.77, reserves of ₹-192 Cr, and liabilities of ₹72 Cr.
What is the Market Cap of Omkar Speciality Chemicals Ltd?
The Market Cap of Omkar Speciality Chemicals Ltd is 10.1 Cr..
What is the current Stock Price of Omkar Speciality Chemicals Ltd as on 06 February 2026?
The current stock price of Omkar Speciality Chemicals Ltd as on 06 February 2026 is ₹4.93.
What is the High / Low of Omkar Speciality Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Omkar Speciality Chemicals Ltd stocks is ₹8.38/4.77.
What is the Stock P/E of Omkar Speciality Chemicals Ltd?
The Stock P/E of Omkar Speciality Chemicals Ltd is .
What is the Book Value of Omkar Speciality Chemicals Ltd?
The Book Value of Omkar Speciality Chemicals Ltd is 83.0.
What is the Dividend Yield of Omkar Speciality Chemicals Ltd?
The Dividend Yield of Omkar Speciality Chemicals Ltd is 0.00 %.
What is the ROCE of Omkar Speciality Chemicals Ltd?
The ROCE of Omkar Speciality Chemicals Ltd is 10.5 %.
What is the ROE of Omkar Speciality Chemicals Ltd?
The ROE of Omkar Speciality Chemicals Ltd is %.
What is the Face Value of Omkar Speciality Chemicals Ltd?
The Face Value of Omkar Speciality Chemicals Ltd is 10.0.